ReviewHuman cell2026
Neutrophil plasticity in inflammation resolution: mechanisms and therapeutic potential.
Review in Human cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
As primary effector cells of the innate immune response, neutrophils exert pivotal regulatory effects on inflammatory responses at the initiation, amplification and resolution stages. This dynamic nature is apparent in multilayered signaling responses, functional plasticity and their mutual actions within the immune network. During early inflammation, neutrophils are rapidly recruited to sites of injury or infection through chemotactic axes, including the interleukin (IL)-8/C-X-C chemokine receptor (CXCR)1/2 axis and the C-X-C motif chemokine ligand 2/CXCR2 axis, as well as by pro-inflammatory cytokines such as interleukin-1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α). At these sites, they destroy pathogens by phagocytosis, by producing reactive oxygen species (ROS), and through the release of so-called neutrophil extracellular traps (NETs). At the intermediate phase, activation of signaling pathways including nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) leads to neutrophil activation and immunity amplification, while NETs support the equilibrium by regulating macrophage, dendritic cell, and T lymphocyte activities. Neutrophil apoptosis and subsequent macrophage-mediated efferocytosis contribute to limiting inflammatory activity and promoting tissue repair during resolution of inflammation; by contrast neutrophil-associated anti-inflammatory and pro-resolving responses, which vary according to the inflammatory context, exhibit a more complex role. Heterogeneous neutrophil populations and functional states in chronic inflammatory lesions and the tumor microenvironment (TME) may show divergent effects on tissue injury and repair. Neutrophils with primarily pro-inflammatory functions can sustain inflammation and tissue destruction, whereas neutrophils displaying anti-inflammatory or reparative programs may contribute to the repair of damaged tissues and the re-establishment of homeostasis. Together, neutrophils perform stage-specific actions across the inflammatory continuum, and their spatiotemporal fine-tuning and signal redirection could become potential targets for precise treatment of infections, autoimmunity, and tumor-related inflammation.
Indexed as
Identifiers
42905373What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.